BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...at $31.44 on Wednesday.Two other companies —vTv Therapeutics Inc....
...One missed and one met.On Dec. 15,  vTv...
...—and has been shown bind β amyloid.vTv...
BioCentury | Dec 16, 2020
Deals

Dec. 15 Quick Takes: Singlera raises $150M for cancer dx; plus AnGes-Emendo, Entresto, vTv and Unity

...HFpEF). A decision by FDA is expected next quarter. Novartis AG (NYSE:NVS; SIX:NOVN) markets the drug.vTv...
...assessed by the 14-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo. vTv...
...and EVP of R&D of Sarepta Therapeutics Inc. (NASDAQ:SRPT). Jeff Cranmer Entresto, sacubitril/valsartan (LCZ696) azeliragon (TTP488, PF-04494700, PF-4494700) Singlera AnGes Emendo Biotherapeutics vTv...
BioCentury | Dec 9, 2020
Deals

Reneo to start pivotal trial in mitochondrial diseases, build orphan pipeline with Novo, Abingworth-led $95M series B

...the end of 2021 or early 2022. Another private round is unlikely.Reneo licensed REN001 from vTv Therapeutics Inc....
...to start building its commercial infrastructure.Flesher declined to give specific details on Reneo’s obligation to vTv...
BioCentury | Feb 11, 2020
Product Development

vTv’s potential first-in-class therapy heading for Phase III after clearing Type I diabetes hurdle

...Based on the 52% bump that vTv’s shares received on Monday, investors believe new data from...
...therapy, TTP399, can become a first-in-class oral adjunctive treatment to insulin for Type I diabetics. vTv Therapeutics Inc....
...to a reduction of 0.21% in the treatment group vs. a 0.11% increase for placebo. vTv...
BioCentury | Jul 18, 2019
Distillery Therapeutics

Inhibition of BACH1 or the genes it controls for metastatic lung cancer

...plc and Cancer Research Technology Ltd. have AZD3965 in Phase I/II testing for advanced cancer. vTv Therapeutics Inc....
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...mitochondrial diseases space. Reneo Pharmaceuticals Inc. is developing PPARδ agonist REN001, which it licensed from vTv Therapeutics Inc....
...include Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners, of which O’Donnell is managing director. vTv...
...I Founded: 2014 by Niall O’Donnell, Mike Grey, Susan Dubé University collaborators: None Corporate partners: vTv Therapeutics Inc....
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...are for neuroinflammation indications; some products are more advanced in other indications. (A) Last year, vTv Therapeutics Inc....
...Sanofi (Euronext:SAN; NASDAQ:SNY) DNL747 ALS, AD Ph Ib Other Receptor for advanced glycation endproducts (RAGE) vTv Therapeutics Inc....
BioCentury | Mar 19, 2019
Distillery Therapeutics

Inhibiting BACH1 sensitizes triple-negative breast cancer to metformin

...vehicle. Next steps include seeking partners for clinical testing of metformin with undisclosed BACH1 inhibitors. vTv Therapeutics Inc....
BioCentury | Jun 15, 2018
Clinical News

vTv to propose path forward for AD candidate despite Phase III miss

...path forward for azeliragon based on pooled data from a subgroup of patients. In April, vTv...
...AD Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) score by 2.3 points compared with placebo. vTv Therapeutics Inc....
...Daily Living Inventory (ADCS-ADL) Status: Additional Phase III data Milestone: NA Jaime De Leon azeliragon (TTP488, PF-04494700, PF-4494700) vTv Therapeutics Inc. Receptor...
BioCentury | Jun 1, 2018
Company News

vTv, Newsoara in PDE-4 deal

...in China, including Hong Kong and Macau, and Taiwan as well as other Asian countries. vTv...
...Tokyo:4502). vTv Therapeutics Inc. (NASDAQ:VTVT), High Point, N.C. Newsoara Biopharma Co. Ltd., Shanghai, China Business: Pulmonary, Inflammation Chris Lieu HPP737 vTv Therapeutics Inc. Phosphodiesterase-4...
Items per page:
1 - 10 of 33
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

...at $31.44 on Wednesday.Two other companies —vTv Therapeutics Inc....
...One missed and one met.On Dec. 15,  vTv...
...—and has been shown bind β amyloid.vTv...
BioCentury | Dec 16, 2020
Deals

Dec. 15 Quick Takes: Singlera raises $150M for cancer dx; plus AnGes-Emendo, Entresto, vTv and Unity

...HFpEF). A decision by FDA is expected next quarter. Novartis AG (NYSE:NVS; SIX:NOVN) markets the drug.vTv...
...assessed by the 14-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo. vTv...
...and EVP of R&D of Sarepta Therapeutics Inc. (NASDAQ:SRPT). Jeff Cranmer Entresto, sacubitril/valsartan (LCZ696) azeliragon (TTP488, PF-04494700, PF-4494700) Singlera AnGes Emendo Biotherapeutics vTv...
BioCentury | Dec 9, 2020
Deals

Reneo to start pivotal trial in mitochondrial diseases, build orphan pipeline with Novo, Abingworth-led $95M series B

...the end of 2021 or early 2022. Another private round is unlikely.Reneo licensed REN001 from vTv Therapeutics Inc....
...to start building its commercial infrastructure.Flesher declined to give specific details on Reneo’s obligation to vTv...
BioCentury | Feb 11, 2020
Product Development

vTv’s potential first-in-class therapy heading for Phase III after clearing Type I diabetes hurdle

...Based on the 52% bump that vTv’s shares received on Monday, investors believe new data from...
...therapy, TTP399, can become a first-in-class oral adjunctive treatment to insulin for Type I diabetics. vTv Therapeutics Inc....
...to a reduction of 0.21% in the treatment group vs. a 0.11% increase for placebo. vTv...
BioCentury | Jul 18, 2019
Distillery Therapeutics

Inhibition of BACH1 or the genes it controls for metastatic lung cancer

...plc and Cancer Research Technology Ltd. have AZD3965 in Phase I/II testing for advanced cancer. vTv Therapeutics Inc....
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...mitochondrial diseases space. Reneo Pharmaceuticals Inc. is developing PPARδ agonist REN001, which it licensed from vTv Therapeutics Inc....
...include Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners, of which O’Donnell is managing director. vTv...
...I Founded: 2014 by Niall O’Donnell, Mike Grey, Susan Dubé University collaborators: None Corporate partners: vTv Therapeutics Inc....
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...are for neuroinflammation indications; some products are more advanced in other indications. (A) Last year, vTv Therapeutics Inc....
...Sanofi (Euronext:SAN; NASDAQ:SNY) DNL747 ALS, AD Ph Ib Other Receptor for advanced glycation endproducts (RAGE) vTv Therapeutics Inc....
BioCentury | Mar 19, 2019
Distillery Therapeutics

Inhibiting BACH1 sensitizes triple-negative breast cancer to metformin

...vehicle. Next steps include seeking partners for clinical testing of metformin with undisclosed BACH1 inhibitors. vTv Therapeutics Inc....
BioCentury | Jun 15, 2018
Clinical News

vTv to propose path forward for AD candidate despite Phase III miss

...path forward for azeliragon based on pooled data from a subgroup of patients. In April, vTv...
...AD Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) score by 2.3 points compared with placebo. vTv Therapeutics Inc....
...Daily Living Inventory (ADCS-ADL) Status: Additional Phase III data Milestone: NA Jaime De Leon azeliragon (TTP488, PF-04494700, PF-4494700) vTv Therapeutics Inc. Receptor...
BioCentury | Jun 1, 2018
Company News

vTv, Newsoara in PDE-4 deal

...in China, including Hong Kong and Macau, and Taiwan as well as other Asian countries. vTv...
...Tokyo:4502). vTv Therapeutics Inc. (NASDAQ:VTVT), High Point, N.C. Newsoara Biopharma Co. Ltd., Shanghai, China Business: Pulmonary, Inflammation Chris Lieu HPP737 vTv Therapeutics Inc. Phosphodiesterase-4...
Items per page:
1 - 10 of 33